Nek4 Status Differentially Alters Sensitivity to Microtubule Poisons

2011 February 1

Bibliographic Details
Main Authors: Doles, Jason D. (Contributor), Hemann, Michael (Contributor)
Other Authors: Massachusetts Institute of Technology. Department of Biology (Contributor), Koch Institute for Integrative Cancer Research at MIT (Contributor)
Format: Article
Language:English
Published: American Association for Cancer Research, 2012-10-04T20:08:03Z.
Subjects:
Online Access:Get fulltext
LEADER 02004 am a22002653u 4500
001 73627
042 |a dc 
100 1 0 |a Doles, Jason D.  |e author 
100 1 0 |a Massachusetts Institute of Technology. Department of Biology  |e contributor 
100 1 0 |a Koch Institute for Integrative Cancer Research at MIT  |e contributor 
100 1 0 |a Doles, Jason D.  |e contributor 
100 1 0 |a Hemann, Michael  |e contributor 
700 1 0 |a Hemann, Michael  |e author 
245 0 0 |a Nek4 Status Differentially Alters Sensitivity to Microtubule Poisons 
246 3 3 |a Nek4 Status Differentially Alters Sensitivity to Distinct Microtubule Poisons 
260 |b American Association for Cancer Research,   |c 2012-10-04T20:08:03Z. 
856 |z Get fulltext  |u http://hdl.handle.net/1721.1/73627 
520 |a 2011 February 1 
520 |a Microtubule poisons are widely used in cancer treatment, but the factors determining the relative efficacy of different drugs in this class remain obscure. In this study, we identified the NIMA kinase Nek4 in a genetic screen for mediators of the response to Taxol, a chemotherapeutic agent that stabilizes microtubules. After Taxol treatment, Nek4 promoted microtubule outgrowth, whereas Nek4 deficiency impaired G2-M arrest and decreased formation of mitotic-like asters. In contrast, Nek4 deficiency sensitized cells to vincristine, which destabilizes microtubules. Therefore, Nek4 deficiency may either antagonize or agonize the effects of microtubule poisons, depending on how they affect microtubule polymerization. Of note, Nek4 gene maps to a commonly deleted locus in non-small cell lung cancer. Thus, Nek4 deletion in this disease may rationalize the use of particular types of microtubule poisons for lung cancer therapy. 
520 |a Rita Allen Foundation (Fellow) 
520 |a National Institutes of Health (U.S.) (Grant RO1 CA128803-01) 
520 |a Massachusetts Institute of Technology. Dept. of Biology (Training Grant) 
546 |a en_US 
655 7 |a Article 
773 |t Cancer Research